The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience

A. K. Burnett, S. Freeman, R. K. Hills, A. E. Hunter,D. W. Milligan,W. J. Kell, K. Wheatley,J. A. L. Yin,S. Ali,L. Kjeldsen,A. H. Goldstone,D. Bowen, N. H. Russell

British Journal of Haematology(2012)

引用 0|浏览13
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要